^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

WTX-124

i
Other names: WTX-124, WTX124, WTX 124
Associations
Trials
Company:
Werewolf Therap
Drug class:
IL-2 stimulant
Related drugs:
Associations
Trials
over2years
New P1 trial • Combination therapy
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • WTX-124
over2years
Discovery of a Conditionally Activated Interleukin-2 that Promotes Anti-tumor Immunity and Induces Tumor Regression. (PubMed, Cancer Immunol Res)
Mechanistically, WTX-124 treatment triggered the activation of T cells and natural killer cells, and markedly shifted the immune activation profile of the tumor microenvironment, resulting in significant inhibition of tumor growth in syngeneic tumor models. Collectively, these data demonstrate that WTX-124 minimizes the toxicity of IL-2 treatment in the periphery while retaining the full pharmacology of IL-2 in the tumor microenvironment, supporting its further development as a cancer immunotherapy treatment.
Journal
|
IL2 (Interleukin 2)
|
WTX-124
3years
WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models (SITC 2021)
WTX 124 also demonstrated favorable pharmacokinetic and tolerability characteristics in cynomolgus monkeys resulting in minimal release of IL-2 in the periphery. Conclusions The combination of tumor-selective activation of WTX-124 with reduced peripheral toxicities and its favorable pharmacokinetic profile supports moving this compound into clinical development.
Preclinical
|
CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
|
WTX-124
over3years
[VIRTUAL] WTX-124 is an IL-2 pro-drug conditionally activated in tumors and able to induce complete regressions in mouse tumor models (AACR 2021)
In vitro proteolytic activation by human tumor samples will also be presented. The tumor-selective activation of WTX-124 with reduced peripheral toxicities supports its further clinical development.
Preclinical
|
CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
|
WTX-124